---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Economic burden and healthcare resource utilization. Topics: Drug patterns and economic costs, Healthcare costs and resource utilization before and after starting long-term prophylaxis: US commercial claims, Healthcare costs with lanadelumab compared with berotralstat: US claims, Treatment costs over time with lanadelumab: US claims, and 12 further topics. 16 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Drug patterns and economic costs

> “Notably, annualized expenditures for ODT prescriptions, hospitalizations, and ED visits averaged >$200,000, even after initiation of SC LTP.”

Source: [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/)

<a id="topic-2.2.1.8.2-2"></a>

### Healthcare costs and resource utilization before and after starting long-term prophylaxis: US commercial claims

> “A total of 328 patients were included in this analysis.”
> “Most patients (67%) had ≥1 post-index on-demand therapy claim.”
> “During follow-up, 17% and 8% had ≥1 HAE-related ER and inpatient visit, respectively.”
> “Mean annualized total HAE-related healthcare costs per patient were $165,348 pre-LTP and $515,333 post-LTP, driven by increased LTP pharmacy costs (mean $395,845 PPPY) and partially offset by reductions in medical costs (ER/inpatient, mean $8344 PPPY).”
> “This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation.”

Source: [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/)

<a id="topic-2.2.1.8.2-3"></a>

### Healthcare costs with lanadelumab compared with berotralstat: US claims

> “Fifty-seven lanadelumab- and 32 berotralstat-treated patients were included.”
> “Total HAE treatment costs were similar during months 0–6 (lanadelumab, $377,326 vs berotralstat, $373,010), but decreased in months 7–12 ($319,967) and 13–18 ($283,241) of lanadelumab.”
> “On-demand treatment/short-term prophylaxis costs were lower for lanadelumab across the three follow-up periods than for berotralstat during months 0–6 (berotralstat, $60,451; lanadelumab, months 0–6, $46,336, months 7–12, $37,578, months 13–18, $23,968).”
> “all dollar estimates were inflated to 2022 dollars using the medical care component of the Consumer Price Index.”

Source: [Princic et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11963383/)

<a id="topic-2.2.1.8.2-4"></a>

### Treatment costs over time with lanadelumab: US claims

> “Fifty-four lanadelumab users were included; 25 (46%) had evidence of down titration.”
> “Lanadelumab costs decreased from $316,724 to $269,861 to $246,919 in months 0-6, 7-12, and 13-18, respectively (p < .01); total HAE treatment costs decreased from $377,076 to $329,855 to $286,074 in months 0-6, 7-12, and 13-18, respectively (p < .01).”

Source: [Shah et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37395381/)

<a id="topic-2.2.1.8.2-5"></a>

### Direct and indirect costs of on-demand treatment alone: US patient survey

> “Per patient/year direct costs associated with modeled on-demand–only treatment totaled $363,795, with additional indirect socioeconomic costs of $52,576 per patient/year.”
> “Medications comprise the largest component (62.5%) of modeled on-demand–only treatment, at an estimated $227,674 per patient per year.”
> “The second highest component cost was hospitalization for treatment of an HAE attack (22.1%), followed by ED visits (12.5%).”

Source: [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)

<a id="topic-2.2.1.8.2-6"></a>

### Annual per-patient costs by attack severity before current prophylactic agents: US patient survey

> “Total annual per-patient costs are estimated at $42,000 for the average HAE patient, with costs totaling $14,000 for patients with mild attacks, $27,000 for patients with moderate attacks, and $96,000 for patients with severe attacks.”
> “Hospital costs account for 67% of direct medical costs.”
> “Respondents reported high rates of missed work, lost productivity, and lost income, contributing to indirect costs totaling $16,000 annually for the average patient.”

Source: [Wilson et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20408341/)

<a id="topic-2.2.1.8.2-7"></a>

### Resource use after insurance delays or denials of prophylaxis

> “A total of 70% of participants reported an increased frequency of angioedema attacks resulting from insurance delays or denials.”
> “Twenty-five percent of respondents reported more urgent care or emergency department visits.”

Source: [Arora et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37558360/)

<a id="topic-2.2.1.8.2-8"></a>

### On-demand drug costs per member before and after starting long-term prophylaxis: US commercial claims

> “This was a retrospective analysis of medical and pharmacy claims from a commercial database of 17 million lives across the United States.”
> “Among 61 members initiated on LTP for HAE, 52.5% (n=32) started LTP without prior ODT while 47.5% (n=29) previously received ODT.”
> “Overall, ODT spend in this subgroup declined by $1.37M, averaging a $47,358 reduction per member.”
> “After starting LTP, the average ODT utilization per member decreased from 13.6 to 9.7, a 29% reduction.”
> “Despite a more than 5-fold increase in medication costs with the initiation of LTP, over one-third of members continued to require ODT without reduction.”

Source: [Heuring et al. (2026)](https://www.primetherapeutics.com/documents/d/primetherapeutics/EVT_EXT_670100-H_AMCPPstr_RealWorldPatternsOfOnDemandUtilization_R4-2_Web)

| Population | Allowed cost per member, pre-LTP | Allowed cost per member, post-LTP | Change in allowed cost per member | Percent change |
| --- | --- | --- | --- | --- |
| On-demand therapy experienced cohort (N = 29) | “$108,748” | “$61,390” | “-$47,358” | “-43.6%” |

Source: [Heuring et al. (2026)](https://www.primetherapeutics.com/documents/d/primetherapeutics/EVT_EXT_670100-H_AMCPPstr_RealWorldPatternsOfOnDemandUtilization_R4-2_Web)

<a id="topic-2.2.1.8.2-9"></a>

### Cost per attack treated on demand: Italian prospective cohort

> “To explore treatment behaviours in a cohort of Italian patients with hereditary angioedema due to complement C1-inhibitor deficiency (C1-INH-HAE), and to estimate how effects and costs of treating attacks in routine practice differed across available on-demand treatments.”
> “Cost analyses and survival analyses using attack-level data collected prospectively for 1 year.”
> “Overall, 133 of 167 patients (79.6%) reported 1508 attacks during the study period, with mean incidence of 11 attacks per patient per year.”
> “Only 78.9% of attacks were treated in contrast to current guidelines.”
> “The average cost per attack was €1183 (SD €789) resulting in €1.58 million healthcare costs during the observation period (€11 912 per patient per year).”
> “Icatibant was 54% more expensive than pdC1-INH, whereas age, sex and prophylactic treatment were not associated to higher or lower costs.”

Source: [Federici et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6067408/)

<a id="topic-2.2.1.8.2-10"></a>

### Modeled cost per attack of on-demand treatments: US commercial payer decision model

> “To estimate the cost-effectiveness of on-demand treatment for HAE attacks, a decision-tree model from the U.S. commercial payer perspective was developed using TreeAge Pro 2018 R1 release”
> “All costs are dated to 2019, either directly or by inflation using the medical-care inflation subset of the Consumer Price Index for All Urban Consumers.”
> “The base case model outputs show costs and calculated effectiveness per attack at $12,905 and 0.806 for rhC1-INH, $14,806 and 0.765 for icatibant, $14,668 and 0.769 for pdC1-INH, and $21,068 and 0.792 for ecallantide, respectively.”

Source: [Bernstein et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391298/)

<a id="topic-2.2.1.8.2-11"></a>

### Emergency department and hospital use among users of intravenous C1 inhibitor: US claims

> “The purpose of this retrospective study was to evaluate real-world treatment patterns of HAE-specific medications in the US and to assess their impact on healthcare resource utilization (HCRU).”
> “This analysis used IMS PharMetrics PlusTM database records (2006–2014) of patients with HAE, ≥1 insurance claim for an HAE-specific medication, and continuous insurance enrollment for ≥3 months following the first HAE prescription claim.”
> “Of 631 total patients, 434 (68.8%) reported C1-INH(IV) use; 396 (62.8%) reported using ecallantide and/or icatibant.”
> “There were 306 episodes of prophylactic use of C1-INH(IV) (defined by continuous refills averaging ≥1500 IU/week for ≥13 weeks) in 155 patients; use of ≥1 on-demand rescue medication was implicated during 53% (163/306) of those episodes.”
> “Sixty-eight (20.2%) of 336 C1-INH(IV) users eligible for the HCRU analysis were hospitalized at least once, and 191 (56.8%) visited the emergency department (ED).”
> “This study was funded by CSL Behring.”

Source: [Riedl et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6186115/)

<a id="topic-2.2.1.8.2-12"></a>

### Emergency department visits with hereditary angioedema: Nationwide Emergency Department Sample, 2006 to 2007

> “We evaluated epidemiology, resource use, and discharge destinations of HAE (International Classification of Diseases, Version 9, clinical modification [ICD-9-CM] code 277.6) ED visits within the Nationwide Emergency Department Sample, part of Agency for Healthcare Research and Quality Healthcare Costs and Utilization Project, in 2006 and 2007.”
> “In 2006-2007, there were 5040 ED visits with HAE, of which 2705 (53.7%) had HAE as the principal diagnosis (HAE-PD).”
> “Two thousand fifty-nine (40.9%) resulted in a hospitalization.”
> “Mean HAE ED visits costs were $1479 (95% confidence interval, $1028-1929).”

Source: [Zilberberg et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22195693/)

<a id="topic-2.2.1.8.2-13"></a>

### Hospitalizations and emergency department visits with hereditary angioedema: nationally representative inpatient and emergency department samples, 2007

> “We examined hospitalizations and ED utilization for HAE and AE in two large nationally representative databases.”
> “We also used AHRQ-HCUP's 2007 Nationwide Emergency Department Sample (NEDS) to study annual rates of ED visits and subsequent hospitalizations with these conditions.”
> “There were 1691 hospitalizations with HAE and 22,572 with AE (4.25 HAE and 57.08 AE cases/100,000 hospitalizations).”
> “In aggregate, HAE and AE PD hospitalizations accrued 35,000 hospital days and hospital costs of $63 million.”
> “There were 2282 ED visits with HAE and 112,105 ED visits with AE (1.87 HAE and 91.64 AE cases/100,000 ED visits).”
> “Forty-five percent of HAE patients and 18.3% of AE patients required hospitalization.”

Source: [Zilberberg et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20964950/)

<a id="topic-2.2.1.8.2-14"></a>

### Attack-related medical visits and provider-administered on-demand treatment before and after berotralstat: US claims

> “To evaluate all-cause, angioedema-related, and HAE attack–related medical visits and hospitalizations before and after initiation of berotralstat long-term prophylaxis (LTP) for patients with HAE in the United States.”
> “This retrospective pre-post analysis used Komodo’s Healthcare Map claims data to identify patients who initiated berotralstat (December 2020 to December 2022).”
> “The study population included 260 patients treated with berotralstat (mean age = 39.7 years; 74.2% female).”
> “When stratifying by type of care setting, rates of HAE attack–related IP episodes decreased by 60% (from 0.28 to 0.11 PPY, P < 0.001) and OP/ED episodes decreased by 50% (from 1.46 to 0.74 PPY, P < 0.001) after berotralstat initiation.”
> “Following berotralstat initiation, the rates of on-demand medication administered by a provider decreased significantly by 32% (from 1.17 to 0.87 PPY, P = 0.002) among all patients”
> “Medical writing assistance was provided by Molly Gingrich, an employee of Groupe d’Analyze, Ltée, which received funding from BioCryst Pharmaceuticals for this study”

Source: [Christiansen et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12123198/)

<a id="topic-2.2.1.8.2-15"></a>

### Medical care, activity loss, and missed work or school: European patient survey

> “The study was conducted in Spain, Germany, and Denmark to assess the real-world experience of HAE via a cross-sectional survey of HAE patients, including direct and indirect resource utilization during and between attacks for patients and their caregivers over the past 6 months.”
> “Overall, 164 patients had an attack in the past 6 months and were included in the analysis.”
> “The most significant predictor of medical resource utilization was the severity of the last attack (OR 2.6; p < 0.001).”
> “Among patients who sought medical care during the last attack (23%), more than half utilized the emergency department.”
> “The last attack prevented patients from their normal activities an average of 4–12 hours.”
> “Among patients who were working or in school (n = 120), 72 provided work/school absenteeism data, resulting in an estimated 20 days missing from work/school on average per year; 51% (n = 84) indicated that HAE has hindered their career/educational advancement.”
> “The study was funded by ViroPharma SPRL-BVBA.”

Source: [Aygören-Pürsün et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4105891/)

<a id="topic-2.2.1.8.2-16"></a>

### Societal costs: Dutch patient survey

> “Adult patients with HAE under treatment at the Dutch national center of reference completed a cross-sectional survey in 2021.”
> “The response rate was 78% (69 of 88).”
> “On average, total costs per year incurred €22,764, predominantly existing of HAE-medication costs.”
> “Total costs showed substantial variation between patients.”

Source: [Fijen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36990433/)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
